Buprenorphine

규격

52485-79-7CAS 번호

257-950-6EC 번호

(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-olIUPAC 명칭

C29H41NO4화학식

467.6 g/mol분자량

buprenorphine; Temgesic; 52485-79-7; Buprenophine; Buprenorfina; Buprenorphinum; Butrans; (-)-buprenorphine; buprenorphin; Sublocade; Brixadi; CHEBI:3216; 40D3SCR4GZ; CAM2038; DTXSID2022705; Transtec; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; ALKS-5461 COMPONENT BUPRENORPHINE; (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol; 2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5-alpha,7-alpha-(S))-; Hapoctasin; Bupeaze; Buplast; Panitaz; Prenotrix; Reletrans; Sevodyne; Tephine; Zorbium; Butec; (1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-((2S)-2-hydroxy-3,3-dimethylbutan-2-yl)-15-methoxy-13-oxa-3-azahexacyclo(13.2.2.1^(2,8).0^(1,6).0^(6,14).0^(7,12))icosa-7(12),8,10-trien-11-ol; (1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-((2S)-2-hydroxy-3,3-dimethylbutan-2-yl)-15-methoxy-13-oxa-3-azahexacyclo(13.2.2.1^(2,8).0^(1,6).0^(6,14).0^(7,12))icosa-7,9,11-trien-11-ol; (1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7(12),8,10-trien-11-ol; (1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7,9,11-trien-11-ol; (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-((2S)-2-hydroxy-3,3-dimethylbutan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo(13.2.2.12,8.01,6.02,14.012,20)icosa-8(20),9,11-trien-11-ol; 2-(3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo(13.2.2.12,8.01,6.06,14.07,12)icosa-7,9,11-trien-16-yl)-3,3-dimethyl-2-butanol; 21-cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; RX-6029-M; RefChem:5623; buprenorphine transdermal system; DTXCID602705; N02AE01; N07BC01; RX6029M; RX 6029 M; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5alpha,7alpha(S))-; 6029M; 6029 M; (1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-((2S)-2-hydroxy-3,3-dimethylbutan-2-yl)-15-methoxy-13-oxa-3-azahexacyclo(13.2.2.12,8.01,6.06,14.07,12)icosa-7,9,11-trien-11-ol; 257-950-6; Buprenex; Buprenorfina [INN-Spanish]; Buprenorphinum [INN-Latin]; DEA No. 9064; RX 6029M; Probuphenine; Buprenorphine (1.0mg/ml in Methanol); Buprenorphine (1mg/ml in Acetonitrile); Temgesic (TN); Buprenorphine (JAN/INN); UNII-40D3SCR4GZ; Buvidal; Buprenorphine [INN:BAN:JAN]; 6029-M; EINECS 257-950-6; BEMA; Buprenorphine, free base; [5alpha,7alpha(S)]-; BUPRENORPHINE [MI]; BUPRENORPHINE [INN]; BUPRENORPHINE [JAN]; Buprenorphine CRS - * psy; Epitope ID:2278422; SCHEMBL15821; BUPRENORPHINE [VANDF]; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; BUPRENORPHINE [MART.]; BUPRENORPHINE [WHO-DD]; GTPL1670; BUPRENORPHINE [EMA EPAR]; RMRJXGBAOAMLHD-IHFGGWKQSA-N; BUPRENORPHINE [EP IMPURITY]; BUPRENORPHINE [ORANGE BOOK]; Sixmo (buprenorphine hydrochloride); RBP-6000; BUPRENORPHINE [EP MONOGRAPH]; BDBM50026603; Buprenorphine 0.1 mg/ml in Methanol; Buprenorphine 1.0 mg/ml in Methanol; DB00921; Buprenorphine (1 mg/ml in Acetonitrile); (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-.alpha.-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-.alpha.-methyl-, (.alpha.S,5.alpha.,7.alpha.)-; C08007; D07132; Buprenorphine For System Suitability CRS - * Psy; Q407721; SA1 - Drugs for the Treatment of substance related disorders 1; (18R)-17-(Cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-5alpha,6beta,14beta-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; (2S)-2-[(5R,6R,7R,14S)-9alpha-Cyclopropylmethyl-3-hydroxy-6-methoxy-4,5-epoxy-6,14-ethanomorphinan-7-yl]-3,3-dimethylbutan-2-ol; [5?,7?(S)]-17-(Cyclopropylmethyl)-?-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-?-methyl-6,14-ethenomorphinan-7-methanol;; 6,14-ethenomorphinan-3-ol, 17-(cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-7-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-, (5alpha,7alpha)-; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-,; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)- (9CI)동의어